A phase I dose escalation trial of BIBW2992 administration for 20, 13, or 6 days in combination with docetaxel every 21 days

Trial Profile

A phase I dose escalation trial of BIBW2992 administration for 20, 13, or 6 days in combination with docetaxel every 21 days

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2014

At a glance

  • Drugs Afatinib (Primary) ; Docetaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top